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ABSTRACT
The overall survival with follicular lymphoma has not significantly changed over the last few decades, and there
is no universal agreement as to the optimal first-line or subsequent therapy. High-dose chemotherapy with
autologous hematopoietic cell transplantation (HCT) confers high response rates and improved progression-
free survival in advanced-stage disease, and more recent data indicate a positive effect on overall survival. Initial
results with myeloablative allogeneic HCT unequivocally demonstrated a reduction in relapse/progression
compared with autologous HCT, but it is associated with prohibitive nonrelapse mortality. Nonmyeloablative
or reduced-intensity regimens have substantially reduced up-front toxicity, and preliminary data seem highly
encouraging with regard to efficacy. Novel strategies include the use of rituximab for in vivo purging and
maintenance therapy. The incorporation of radioimmunoconjugates into conditioning regimens to deliver
targeted radiotherapy also appears promising. This review summarizes current and new developments regard-
ing the role of HCT for patients with follicular lymphoma.
© 2006 American Society for Blood and Marrow Transplantation
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Although patients with follicular lymphoma (FL)
ypically experience a relatively indolent disease course,
his disease is rarely curable with conventional chemo-
herapy. Although most patients achieve a remission
ith initial chemotherapy, subsequent remissions be-
ome progressively shorter over time [1,2]. In light of
he discouraging results with conventional chemo-
herapy, autologous and allogeneic hematopoietic cell
ransplantation (HCT) have been evaluated as alter-
ative approaches. It should be noted, however, that
ost currently published trials were initiated in the
rerituximab era. Therefore, there is still a paucity of
ata regarding the inﬂuence of rituximab on the out-
omes in patients undergoing HCT.
UTOLOGOUS HCT
elapsed Follicular Non-Hodgkin’s Lymphoma
For patients with relapsed follicular non-Hodgkin’s
ymphoma (NHL) undergoing autologousHCT (AHCT),
everal studies have consistently shown improved dis- r
B&MTase-free survival (DFS) after salvage therapy but have
hown no conclusive beneﬁt in overall survival (OS)
ntil recently (Table 1). A European group of inves-
igators conducted the ﬁrst randomized trial, the Che-
otherapy vs Unpurged arm vs Purged arm (CUP)
rial, that prospectively addressed the role of AHCT
n this patient population [3]. In this trial, 140 patients
ith relapsed, chemosensitive follicular NHL were
andomized to chemotherapy alone, AHCT with a
urged autograft, or AHCT with an unpurged au-
ograft. OS at 4 years for the chemotherapy arm,
npurged AHCT arm, and purged AHCT arm was
6%, 71%, and 77%, respectively. The 2-year pro-
ression-free survival (PFS) was 26%, 58%, and 55%,
espectively. There was a signiﬁcant reduction in haz-
rd rates for both PFS and OS when comparing the
hemotherapy patients and the combined groups of
HCT patients. There was no difference between the
AHCT arms in these end points, although too few
atients were accrued in these 2 arms to evaluate the
ffect of ex vivo purging. These results are the ﬁrst to
emonstrate an OS beneﬁt of AHCT for patients with
elapsed follicular NHL.
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Table 1. Autologous Hematopoietic Cell Transplantation for Follicular NHL
Study n Preparative Regimen Stem Cell Source
DFS/PFS
(%)
OS
(%) Years
TRM
(%)
Incidence of Secondary
MDS/AML
(%)
First remission
GOELAMS [7] 2005 (randomized) 82 CHVP  IFN 48 84 5 0 0
88 VCAP ¡ TBI/CY Purged PBPC or BM 60* 78† 0 19
GLSG [8] 2004 (randomized) 126 CHOP or MCP  IFN 33 NR 5 <2.5 NR
114 CHOP ¡ dexa-BEAM Unpurged PBPC 64‡ NR <2.5 NR
GITMO [14] 2002 80 High-dose sequential PBPC 67 84 4 2 4
Stanford/COH [34] 2001 37 TBI/VP/CY Purged BM 70 86 10 5 5
GOELAMS [35] 2000 27 CY/TBI Purged BM 55 64 NR 7 NR
Relapsed
CUP (randomized) [3] 2003 24 CHOP  6 NA 26 46 4§ 0 NR
33 CHOP  3, CY/TBI BM 58 71 9
32 CHOP  3, CY/TBI Purged BM 55 77 6
FHCRC [5] 2003 27 Tositumomab Purged BM or PBPC 48 67 5 4 7
Stanford [25] 2001 49 TBI/VP/CY Purged PBPC 44 60 4 10 7
St. Bartholomew’s [10] 2000 99 CY/TBI Purged BM 63 69 5 4 12
Dana-Farber [12] 1999 153 CY/TBI Purged BM 42 66 8 1 8
Nebraska [36] 1997 100 CY/TBI, BEAC BM 44 65 4 8 2
DFS indicates disease-free survival; PFS, progression-free survival; OS, overall survival; TRM, treatment-related mortality; MDS, myelodysplastic syndrome; IFN, interferon; CHVP, cyclosphospha-
mide, doxorubin, teniposide, and prednisone; MCP, mitoxantrone, chlorambucil, and prednisone; VCAP, vincristine, cyclophosphamide, doxorubicin, prednisone; dexa-BEAM, dexamethasone,
carmustine, etoposide, cytarabine, and melphalan; AML, acute myelogenous leukemia; GLSG, German Lymphoma Study Group; GITMO, Gruppo Italiano Trapianto Midollo Ossseo; COH, City
of Hope; PBPC, peripheral blood progenitor cell; TBI, total body irradiation; VP, etoposide; CY, cyclophosphamide; BM, bone marrow; FHCRC, Fred Hutchinson Cancer Research Center; BEAC,
carmustine, etoposide, cytarabine, and cyclophosphamide; NR, not reported; NA, not applicable; CUP, Chemotherapy vs Unpurged arm vs Purged arm; GOELAMS, French Groupe Ouest-des
Leucemies et Autres Maladies du Sang; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone.
*P  .05.
†P  .49.
‡P  .0001.
§For overall survival only.
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HCT for Follicular Non-Hodgkin’s Lymphoma
BAs a method to augment targeted radiation to lym-
homatous sites while reducing toxicity to healthy or-
ans, the Seattle group was the ﬁrst to explore the
easibility of administering myeloablative doses of radio-
mmunotherapy (RIT). The iodine I 131–anti-CD20
onoclonal antibody tositumomab, followed by etopo-
ide and cyclophosphamide with AHCT, was adminis-
ered to 52 relapsed NHL patients, including 38 FL
atients [4]. The combined RIT/high-dose chemo-
herapy regimen was well tolerated and yielded a
-year PFS and OS of 68% and 83%, respectively.
his compared favorably to survival in a nonrandom-
zed control group. Only 1 case of myelodysplastic
yndrome was seen in the 2-year follow-up. This same
roup of investigators subsequently published a mul-
ivariable cohort analysis of 125 patients with FL
reated either with single-agent high-dose tositu-
omab with autologous stem cell rescue or with con-
entional AHCT [5]. The RIT group experienced
igniﬁcantly superior PFS and OS compared with the
istorical high-dose chemotherapy patients (PFS,
8% versus 29%; OS, 67% versus 53%, respectively).
he treatment-related mortality (TRM) risk of
.7% compared favorably with the 11% TRM ob-
erved in the historical high-dose chemotherapy
roup. The Nebraska transplantation team combined
onventional-dose tositumomab with BEAM (carmus-
ine, etoposide, cytarabine, and melphalan) in the
HCT setting in 23 patients with relapsed NHL,
ncluding 4 FL patients. With a median follow-up of
8 months, the event-free survival (EFS) and OS were
9% and 55%, respectively, and reported toxicities
ere comparable to those in historical control patients
ho received BEAM alone [6].
irst Remission
Early intensive therapy in patients with newly di-
gnosed FL or patients in ﬁrst remission has yielded
igh response rates, but the role of high-dose chemo-
herapy with AHCT in this setting is controversial.
everal published series have evaluated the efﬁcacy of
his approach, but only recently has this question been
ddressed in a prospective randomized manner. The
rench Group Ouest-der Leucemies et Autres Mala-
ies du Sang (GOELAMS) group randomized 172
atients with newly diagnosed FL to either an immu-
ochemotherapy regimen (a cyclophosphamide, doxo-
ubicin, vincristine, predisone (CHOP)-like regimen
lus interferon) or AHCT with a purged graft after
atients attained at least a partial remission to induc-
ion chemotherapy [7]. After a median follow-up of 5
ears, the transplantation group experienced a signif-
cantly higher response rate and longer EFS. The
edian EFS was 45 months in the chemotherapy
roup, whereas this end point had not yet been
eached in the transplantation recipients. However, n
B&MThese observations did not translate into a superior OS
or the transplantation group because of an excessive
9% actuarial risk of secondary malignancies in this
roup, versus 0% in the chemotherapy recipients. It is
nteresting to note that when patients were subdivided
y risk category according to the Follicular Lym-
homa International Prognostic Index, the superiority
n EFS among the transplant recipients was seen only
n the poor-risk group. The good- and intermediate-
isk patients in both treatment groups had comparable
utcomes. These results suggest that patients with
oor prognostic factors at diagnosis, such as a poor
ollicular Lymphoma International Prognostic Index,
ay beneﬁt from early intensive therapy. The Ger-
an Low Grade Lymphoma Study Group also re-
ently reported the results of their randomized trial
hat involved 240 patients with FL [8]. All patients
nitially received 2 cycles of an anthracycline-based
egimen and then were randomized to either AHCT
r interferon maintenance therapy until progression.
he 5-year PFS favored the transplantation group
64% versus 33%; P .0001), but the results were not
ufﬁciently mature to report OS. As seen in the
OELAMS trial, a signiﬁcantly increased risk of sec-
ndary malignancies was observed in the transplanta-
ion group after a preliminary analysis; this risk may
egate the beneﬁt of AHCT. On the basis of these
esults, AHCT cannot be recommended for patients
ith newly diagnosed FL.
Mounting evidence has conﬁrmed the prognostic
elevance of molecular monitoring of minimal residual
isease (MRD) in patients with indolent lymphoma
ho are known to express the bcl-2/immunoglobulin
rearrangement. The attainment of polymerase
hain reaction (PCR) negativity after transplantation
eems to be highly predictive of continued complete
emission, as shown in trials from St. Bartholomew’s,
he University of Heidelberg, and an Italian multi-
enter group [9-11]. In the Italian trial, with a median
ollow-up of 75 months, an 88% incidence of relapse
as observed among patients who never attained a
olecular remission, compared with only 8% among
atients who were PCR negative after transplantation.
raft Purging
Contamination of the hematopoietic stem cell
raft by tumor cells is thought to be a major factor
hat contributes to relapse after AHCT. Reducing the
ate of relapse may be achieved by pre-HCT purging
f the hematopoietic stem cell product. Although no
andomized trials to date strongly support the use of
urging, several studies suggest a clinical beneﬁt. The
ana-Farber group demonstrated the effect of suc-
essful in vitro graft purging: the 8-year freedom from
elapse was 83% in the patients who received PCR-
egative grafts, compared with 19% in patients who
61
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6eceived PCR-positive grafts [12]. In a large retrospec-
ive analysis of 904 FL patients by the International Bone
arrow Transplantation Registry (IBMTR), multivari-
te analysis revealed that stem cell purging was an inde-
endent predictor of relapse and OS [13].
Various in vitro purging methods are typically ex-
ensive and labor intensive and can be associated with
ubstantial cell losses. Thus, in vivo purging via inten-
ive induction therapy or with a single agent
uch as rituximab may be a more attractive strategy.
he multicenter Gruppo Italiano Trapianto Midollo
sseo study administered high-dose sequential ther-
py at diagnosis with the goal of harvesting stem cells
fter intensiﬁed chemotherapeutic debulking [14].
early half of the patients (47%) had PCR-negative
rafts, and 65% of patients achieved clinical and mo-
ecular remission. At 4 years, the projected DFS and
S were 67% and 85%, respectively, with an 85%
FS among the patients who achieved a molecular
emission.
For the purpose of in vivo purging, rituximab has
ecently emerged as a promising agent for this pur-
ose when given concurrently with chemotherapy.
hree recent studies have evaluated the effectiveness
f the addition of rituximab to mobilization chemo-
herapy and yielded stem cell harvests with no PCR-
etectable disease in the graft [15-17]. One such study,
y Magni et al. [16], evaluated 15 patients with mantle
ell lymphoma or FL who were given 2 cycles of
ntensive chemotherapy with 2 doses of rituximab.
inety-three percent of the patents who received rit-
ximab had PCR-negative harvests, compared with
nly 40% of patients who had received the identical
hemotherapeutic regimen but without rituximab.
he effect of in vivo purging on clinical outcome is
till unclear but should become more evident as the
ata matures.
istologic Transformation
Histologic transformation (HT) occurs in up to
0% of low-grade lymphoma patients and carries a
edian survival of 1 year after transformation with
onventional chemotherapy [18-20]. However, this
dverse prognosis may be modiﬁed by high-dose che-
otherapy with AHCT, although this is controversial.
nitial reports from Nebraska and the European Group
or Blood and Marrow Transplantation (EBMT) re-
orted poor outcomes after AHCT for this subset of
atients [21,22]. A more recent update from the
BMT found similar outcomes after AHCT for trans-
ormed patients compared with case-matched controls
ith low-grade disease or de novo high- or intermedi-
te-grade disease [23]. Increased lactate dehydroge-
ase at the time of transformation was the only ad-
erse predictive factor for both OS and PFS.
owever, a TRM of 18% was observed, which was A
2imilar to the 20% TRM reported from the Princess
argaret Hospital in another retrospective analysis in
hich TRM was closely linked to advanced age. In the
rincess Margaret study, the median OS for the 35
ransformed patients was a notable 58 months from
he time of transformation; the best outcomes were
een in patients who attained a complete remission
efore transplantation [24]. The Stanford group pub-
ished a 4-year DFS of 49% and an OS of 50% in 17
atients with HT, which was similar to the updated
BMT study [25]. Comparable outcomes after trans-
lantation were also reported by Corradini et al. [11],
ith a 10-year projected EFS of 54% for HT patients
ompared with 65% for patients who retained low-
rade histological characteristics. Together, these data
uggest that patients with HT may beneﬁt from dose-
ntensive chemotherapy, especially patients with che-
osensitive disease, and that HT does not necessarily
ortend a poor outcome.
LLOGENEIC HCT
High-dose chemoradiotherapy with allogeneic HCT
as also been offered to patients with recurrent follic-
lar NHL to harness a graft-versus-lymphoma effect
nd to circumvent the tumor cell contamination asso-
iated with autologous hematopoietic stem cell har-
ests. Although no randomized trials have been per-
ormed, several studies have consistently reported a
ower risk of relapse compared with AHCT. However,
his beneﬁt has been invariably offset by the TRM
ssociated with myeloablative allogeneic HCT. An
pdated analysis from the IBMTR compared the out-
omes of 904 patients with follicular NHL who un-
erwent myeloablative allogeneic HCT (n  176),
urged AHCT (n  131), or unpurged AHCT (n 
97). The risk for relapse was 54% lower in the allo-
eneic recipients (P  .001) and was 26% lower in
ecipients of purged autografts (P  .04) than in re-
ipients of unpurged autografts [13]. Few relapses
ccurred in the allogeneic group after 1 year, as op-
osed to a continuous pattern of treatment failure in
he autologous group. However, in a multivariate
nalysis, the risk of TRM was 4.4 times higher after
llogeneic than after autologous transplantation (P 
001); this resulted in comparable 5-year probabilities
f OS (52% after allogeneic, 62% after purged autol-
gous, and 55% after unpurged autologous transplan-
ation). The use of total body irradiation and receipt
f a purged graft were associated with a lower risk of
ecurrence by multivariate analysis. In another large
egistry series, the EBMT analyzed the outcomes of
185 patients with NHL who underwent myeloabla-
ive HCT, including 231 patients with low-grade
HL, and compared the results with those of 14 687
HCT recipients [26]. As in the IBMTR study, the
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HCT for Follicular Non-Hodgkin’s Lymphoma
Belapse risk was signiﬁcantly lower among the alloge-
eic recipients, but OS was not superior in this group
ecause of the prohibitive TRM of 38% at 4 years. A
igher proportion of the allogeneic group, however,
as more heavily pretreated and underwent transplan-
ation with more advanced disease. Two single-insti-
ution retrospective analyses with myeloablative allo-
eneic HCT from the Vancouver group and M.D.
nderson demonstrated that long-term DFS can be
ttained even in FL patients with chemoresistant dis-
ase [27,28]. In the M.D. Anderson report, plateaus
ere observed for both DFS and OS (24 and 44
onths, respectively) even though nearly half of the
atients had chemoresistant disease before transplan-
ation [28].
onmyeloablative HCT
Nonmyeloablative allogeneic HCT incorporates a
ess intensive preparative regimen and relies primarily
n the immunotherapeutic effects of the allograft to
onfer antitumor activity rather than the cytoreduc-
ive effects of high-dose chemotherapy (Table 2). The
herapeutic beneﬁt of allogeneic HCT is derived from
onor-immunocompetent T cells that mediate an im-
ortant graft-versus-malignancy effect. Some of the
ost promising data with nonmyeloablative alloge-
eic HCT in follicular NHL patients originated from
he M.D. Anderson Cancer Center [29]. Twenty pa-
ients with relapsed indolent NHL, including 18 FL
atients, received a conditioning regimen of ﬂudara-
ine and cyclophosphamide with or without ritux-
mab. All had received salvage chemotherapy, and 12
ere in second or greater complete remission at the
ime of transplantation. The complete response rate
as 100% after transplantation, with no recurrences at
median follow-up of 21 months. DFS and OS at 2
ears were both approximately 84%. The incidence of
rade II to IV acute graft-versus-host disease (GVHD)
as 20%, and the cumulative incidence of chronic
VHDwas 64%. Only 1 patient died from a treatment-
elated complication. These highly encouraging data
learly support the existence of a graft-versus-lymphoma
ffect, although longer follow-up is necessary to conﬁrm
true plateau in survival. Kusumi et al. [30] demon-
trated the efﬁcacy of reduced-intensity conditioning
n 45 patients with indolent NHL, including patients
ith chemoresistant disease. This was a heavily pre-
reated group; the median number of prior regimens
as 4, and some patients had experienced prior treat-
ent failure with AHCT. Patients received a ﬂudara-
ine-based regimen or low-dose total body irradia-
ion. The 3-year OS was 79%, and 3-year PFS was
3% and 64% for the chemosensitive and chemore-
istant patients, respectively. The nonrelapse mortal-
ty was 18%, which was much lower than in the
B&MTT
a
Ja
p 2
U
K
U
K
M
.D
D
F
*G
63
p
m
w
e
T
s
h
C
p
v
r
T
r
s
e
s
g
t
8
t
J
w
t
T
a
p
G
c
p
l
o
ﬂ
p
r
r
3
r
e
t
s
t
t
t
a
p
b
r
t
n
a
i
v
a
S
N
d
d
F
v
r
t
i
r
i
i
d
p
c
H
c
r
c
f
s
n
R
G. G. Laport
6reviously mentioned studies that used ablative regi-
ens. The occurrence of acute GVHD was associated
ith a lower progression rate, although it had no
ffect on PFS.
Although preliminary evidence demonstrates that
RM is reduced with nonmyeloablative HCT, GVHD
till remains a leading cause of mortality. Thus, there
ave been studies that incorporated alemtuzumab (anti–
D-52 humanized monoclonal antibody) into the pre-
arative regimen to ameliorate acute GVHD via in
ivo donor T-cell depletion. Graft rejection is also
educed because recipient T cells are also affected.
wo separate groups from the United Kingdom have
eported remarkably low acute GVHD rates in this
etting; grade III and IV acute GVHD was completely
liminated in the study by Faulkner et al. [31]. In that
tudy, 65 patients, including 28 patients with low-
rade NHL, received a BEAM/alemtuzumab condi-
ioning regimen. Estimated 1-year TRM was only
%, and relapse/progression was the major cause of
reatment failure. Similar to the above-mentioned
apanese study, relapse did not occur in any patient
ho developed acute or chronic GVHD, although
his association did not reach statistical signiﬁcance.
he other series from the United Kingdom, which
lso used an alemtuzumab-containing regimen, re-
orted only a 15% incidence of grade II to IV acute
VHD [32].
The EBMT described the use of reduced-intensity
onditioning for 188 patients with low-grade lym-
homa, including 52 patients with follicular and small
ymphocytic NHL. Twenty-nine percent had previ-
usly received an AHCT. Most patients received a
udarabine-based preparative regimen, and 10% of
atients received BEAM, a more intensive and ablative
egimen. The 2-year PFS and OS were 54% and 65%,
espectively, with a 21% progression rate. TRM was
1%. The use of a more intensive conditioning
egimen most likely contributed to the higher-than-
xpected TRM [33]. An ongoing trial conducted by
he North American Clinical Trials Network is pro-
pectively comparing AHCT with nonmyeloabla-
ive allogeneic HCT for patients with chemosensi-
ive relapsed FL. Patients are assigned to a
reatment strategy on the basis of the availability of
n HLA-matched sibling. This protocol attempts to
reemptively address relapse in the autologous arm
y incorporating rituximab into the mobilization
egimen for in vivo graft purging and by adminis-
ering rituximab after transplantation for mainte-
ance therapy to eradicate MRD. The allogeneic
rm uses ﬂudarabine, cyclophosphamide, and ritux-
mab during conditioning and relies on the graft-
ersus-lymphoma effect for both antitumor efﬁcacy
nd the reduction of MRD.
4UMMARY
The role of allogeneic HCT and AHCT in follicular
HL has shown considerable progress over the past
ecade. Regarding AHCT, there are now recent data
emonstrating an OS beneﬁt in patients with relapsed
L with chemosensitive disease. An abundance of pre-
ious trials have clearly shown improved DFS. With the
ecent incorporation of radioimmunoconjugates such as
ositumomab and monoclonal antibodies such as ritux-
mab into conditioning and mobilization regimens, the
ole and efﬁcacy of AHCT will continue to evolve and,
t is hoped, improve over time for FL patients. The
ncidence of secondary malignancies, especially myelo-
ysplastic syndrome, however, remains a troubling com-
lication after AHCT.
Although relapse and progression occur signiﬁ-
antly less often after myeloablative allogeneic
CT, this modality cannot be recommended be-
ause of its prohibitive TRM. Nonmyeloablative or
educed-intensity regimens have shown highly en-
ouraging results and unequivocally induce less up-
ront toxicity. Longer follow-up, however, is neces-
ary to fully evaluate the long-term effect on the
atural history of FL.
EFERENCES
1. Dana BW, Dahlberg S, Nathwani BN, et al. Long-term
follow-up of patients with low-grade malignant lymphomas
treated with doxorubicin-based chemotherapy or chemoimmu-
notherapy. J Clin Oncol. 1993;11:644-651.
2. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of
survival in patients with recurrent follicular lymphoma: a 20-
year study from a single center. J Clin Oncol. 1995;13:140-147.
3. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy
improves progression-free survival and survival in relapsed fol-
licular non-Hodgkin’s lymphoma: results from the randomized
European CUP trial. J Clin Oncol. 2003;21:3918-3927.
4. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of
iodine-131-tositumomab (anti-CD20), etoposide, cyclophosph-
amide, and autologous stem cell transplantation for relapsed
B-cell lymphomas. Blood. 2000;96:2934-2942.
5. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radio-
immunotherapy versus conventional high-dose therapy and au-
tologous hematopoietic stem cell transplantation for relapsed
follicular non-Hodgkin lymphoma: a multivariable cohort anal-
ysis. Blood. 2003;102:2351-2357.
6. Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131
tositumomab with high-dose chemotherapy and autologous
stem-cell transplantation for relapsed non-Hodgkin’s lym-
phoma. J Clin Oncol. 2005;23:461-467.
7. Deconinck E, Foussard C, Milpied N, et al. High-dose therapy
followed by autologous purged stem-cell transplantation and
doxorubicin-based chemotherapy in patients with advanced follic-
ular lymphoma: a randomized multicenter study by GOELAMS.
Blood. 2005;105:3817-3823.
8. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radio-
chemotherapy followed by autologous stem cell transplantation
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
HCT for Follicular Non-Hodgkin’s Lymphoma
Bin ﬁrst remission prolongs progression-free survival in follicular
lymphoma: results of a prospective, randomized trial of the
German Low-Grade Lymphoma Study Group. Blood.
2004;104:2667-2674.
9. Moos M, Schulz R, Martin S, Benner A, Haas R. The remission
status before and the PCR status after high-dose therapy with
peripheral blood stem cell support are prognostic factors for
relapse-free survival in patients with follicular non-Hodgkin’s
lymphoma. Leukemia. 1998;12:1971-1976.
0. Apostolidis J, Gupta RK, Grenzelias D, et al. High-dose ther-
apy with autologous bone marrow support as consolidation of
remission in follicular lymphoma: long-term clinical and mo-
lecular follow-up. J Clin Oncol. 2000;18:527-536.
1. Corradini P, Ladetto M, Zallio F, et al. Long-term follow-up of
indolent lymphoma patients treated with high-dose sequential
chemotherapy and autografting: evidence that durable molec-
ular and clinical remission frequently can be attained only in
follicular subtypes. J Clin Oncol. 2004;22:1460-1468.
2. Freedman AS, Neuberg D, Mauch P, et al. Long-term fol-
low-up of autologous bone marrow transplantation in pa-
tients with relapsed follicular lymphoma. Blood. 1999;94:
3325-3333.
3. van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison
of autologous and allogeneic hematopoietic stem cell transplan-
tation for follicular lymphoma. Blood. 2003;102:3521-3529.
4. Ladetto M, Corradini P, Vallet S, et al. High rate of clinical
and molecular remissions in follicular lymphoma patients
receiving high-dose sequential chemotherapy and autograft-
ing at diagnosis: a multicenter, prospective study by the
Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood.
2002;100:1559-1565.
5. Ladetto M, Zallio F, Vallet S, et al. Concurrent administration
of high-dose chemotherapy and rituximab is a feasible and
effective chemo/immunotherapy for patients with high-risk
non-Hodgkin’s lymphoma. Leukemia. 2001;15:1941-1949.
6. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo
purging of CD34-containing peripheral blood harvests in man-
tle cell and indolent lymphoma: evidence for a role of both
chemotherapy and rituximab infusion. Blood. 2000;96:864-869.
7. Lazzarino M, Arcaini L, Bernasconi P, et al. A sequence of
immuno-chemotherapy with rituximab, mobilization of in vivo
purged stem cells, high-dose chemotherapy and autotransplant
is an effective and non-toxic treatment for advanced follicular
and mantle cell lymphoma. Br J Haematol. 2002;116:229-235.
8. Horning SJ, Rosenberg SA. The natural history of initially
untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med.
1984;311:1471-1475.
9. Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lym-
phoma: prognostic factors for response and survival. J Clin
Oncol. 1986;4:1470-1480.
0. Acker B, Hoppe RT, Colby TV, Cox RS, Kaplan HS, Rosen-
berg SA. Histologic conversion in the non-Hodgkin’s lympho-
mas. J Clin Oncol. 1983;1:11-16.
1. Schouten HC, Colombat P, Verdonck LF, et al. Autologous
bone marrow transplantation for low-grade non-Hodgkin’s
lymphoma: the European Bone Marrow Transplant Group
experience. EBMT Working Party for Lymphoma Ann Oncol.
1994;5(suppl 2):147-149.
2. Schouten HC, Bierman PJ, Vaughan WP, et al. Autologous
bone marrow transplantation in follicular non-Hodgkin’s lym-
phoma before and after histologic transformation. Blood. 1989;
74:2579-2584.
B&MT3. Williams CD, Harrison CN, Lister TA, et al. High-dose ther-
apy and autologous stem-cell support for chemosensitive trans-
formed low-grade follicular non-Hodgkin’s lymphoma: a case-
matched study from the European Bone Marrow Transplant
Registry. J Clin Oncol. 2001;19:727-735.
4. Chen CI, CrumpM, Tsang R, Stewart AK, Keating A. Autotrans-
plants for histologically transformed follicular non-Hodgkin’s
lymphoma. Br J Haematol. 2001;113:202-208.
5. Cao TM, Horning S, Negrin RS, et al. High-dose therapy and
autologous hematopoietic-cell transplantation for follicular
lymphoma beyond ﬁrst remission: the Stanford University ex-
perience. Biol Blood Marrow Transplant. 2001;7:294-301.
6. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT
registry matched study of allogeneic stem cell transplants for
lymphoma: allogeneic transplantation is associated with a lower
relapse rate but a higher procedure-related mortality rate than
autologous transplantation. Bone Marrow Transplant. 2003;31:
667-678.
7. Toze CL, Barnett MJ, Connors JM, et al. Long-term disease-
free survival of patients with advanced follicular lymphoma
after allogeneic bone marrow transplantation. Br J Haematol.
2004;127:311-321.
8. Hosing C, Saliba RM, McLaughlin P, et al. Long-term results
favor allogeneic over autologous hematopoietic stem cell trans-
plantation in patients with refractory or recurrent indolent
non-Hodgkin’s lymphoma. Ann Oncol. 2003;14:737-744.
9. Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic
hematopoietic transplantation as adoptive immunotherapy for
indolent lymphoma: low incidence of toxicity, acute graft-
versus-host disease, and treatment-related mortality. Blood.
2001;98:3595-3599.
0. Kusumi E, Kami M, Kanda Y, et al. Reduced-intensity hema-
topoietic stem-cell transplantation for malignant lymphoma: a
retrospective survey of 112 adult patients in Japan. Bone Marrow
Transplant. 2005;36:205-213.
1. Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtu-
zumab reduced-intensity allogeneic stem cell transplantation
for lymphoproliferative diseases: GVHD, toxicity, and survival
in 65 patients. Blood. 2004;103:428-434.
2. Morris E, Thomson K, Craddock C, et al. Outcomes after
alemtuzumab-containing reduced-intensity allogeneic trans-
plantation regimen for relapsed and refractory non-Hodgkin
lymphoma. Blood. 2004;104:3865-3871.
3. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemore-
sistant or aggressive lymphoma predicts for a poor outcome
following reduced-intensity allogeneic progenitor cell trans-
plantation: an analysis from the Lymphoma Working Party of
the European Group for Blood and Bone Marrow Transplan-
tation. Blood. 2002;100:4310-4316.
4. Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy
and autologous bone marrow transplantation for follicular lym-
phoma in ﬁrst complete or partial remission: results of a phase
II clinical trial. Blood. 2001;97:404-409.
5. Colombat P, Cornillet P, Deconinck E, et al. Value of autolo-
gous stem cell transplantation with purged bone marrow as
ﬁrst-line therapy for follicular lymphoma with high tumor
burden: a GOELAMS phase II study. Bone Marrow Transplant.
2000;26:971-977.
6. Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A,
Armitage JO. High-dose therapy with autologous hematopoi-
etic rescue for follicular low-grade non-Hodgkin’s lymphoma.
J Clin Oncol. 1997;15:445-450.
65
